Abstract
A Phase I study of recombinant gamma-interferon was conducted in 35 patients with advanced malignancy. The schedule was twice weekly administered intravenously. Patients were assigned to six dose levels. The major toxicities were flu-like symptoms and were unrelated to dose. Other adverse reactions, such as myelosuppression, were dose dependent. The addition of a nonsteroidal anti-inflammatory agent did not ameliorate the symptoms at the highest dose level. Antitumor effects occurred in patients with gastric, duodenal, and breast carcinoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 438-446 |
| Number of pages | 9 |
| Journal | Journal of Biological Response Modifiers |
| Volume | 7 |
| Issue number | 5 |
| State | Published - Oct 1988 |
Keywords
- Adverse reactions
- Malignancy
- Recombinant gamma-interferon
ASJC Scopus subject areas
- Immunology
- Pharmacology
- Cancer Research